Home > Publications Database > Microglia activation orchestrates CXCL10-mediated CD8+ T cell recruitment to promote aging-related white matter degeneration. > print

001     279051
005     20250713001357.0
024 7 _ |a 10.1038/s41593-025-01955-w
|2 doi
024 7 _ |a pmid:40404995
|2 pmid
024 7 _ |a 1097-6256
|2 ISSN
024 7 _ |a 1546-1726
|2 ISSN
024 7 _ |a altmetric:177326840
|2 altmetric
037 _ _ |a DZNE-2025-00681
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Groh, Janos
|0 P:(DE-2719)9002589
|b 0
|e First author
245 _ _ |a Microglia activation orchestrates CXCL10-mediated CD8+ T cell recruitment to promote aging-related white matter degeneration.
260 _ _ |a New York, NY
|c 2025
|b Nature America
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1749560104_18361
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Aging is the major risk factor for neurodegeneration and is associated with structural and functional alterations in white matter. Myelin is particularly vulnerable to aging, resulting in white matter-associated microglia activation. Here we used pharmacological and genetic approaches to investigate microglial functions related to aging-associated changes in myelinated axons of mice. Our results reveal that maladaptive microglia activation promotes the accumulation of harmful CD8+ T cells, leading to the degeneration of myelinated axons and subsequent impairment of brain function and behavior. We characterize glial heterogeneity and aging-related changes in white matter by single-cell and spatial transcriptomics and reveal elaborate glial-immune interactions. Mechanistically, we show that the CXCL10-CXCR3 axis is crucial for the recruitment and retention of CD8+ T cells in aged white matter, where they exert pathogenic effects. Our results indicate that myelin-related microglia dysfunction promotes adaptive immune reactions in aging and identify putative targets to mitigate their detrimental impact.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Chemokine CXCL10
|2 NLM Chemicals
650 _ 7 |a Receptors, CXCR3
|2 NLM Chemicals
650 _ 7 |a Cxcl10 protein, mouse
|2 NLM Chemicals
650 _ 7 |a Cxcr3 protein, mouse
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Microglia: immunology
|2 MeSH
650 _ 2 |a Microglia: metabolism
|2 MeSH
650 _ 2 |a White Matter: pathology
|2 MeSH
650 _ 2 |a White Matter: immunology
|2 MeSH
650 _ 2 |a White Matter: metabolism
|2 MeSH
650 _ 2 |a CD8-Positive T-Lymphocytes: immunology
|2 MeSH
650 _ 2 |a CD8-Positive T-Lymphocytes: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Aging: pathology
|2 MeSH
650 _ 2 |a Aging: immunology
|2 MeSH
650 _ 2 |a Chemokine CXCL10: metabolism
|2 MeSH
650 _ 2 |a Chemokine CXCL10: immunology
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Receptors, CXCR3: metabolism
|2 MeSH
650 _ 2 |a Myelin Sheath
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Mice, Transgenic
|2 MeSH
650 _ 2 |a Nerve Degeneration: pathology
|2 MeSH
650 _ 2 |a Nerve Degeneration: immunology
|2 MeSH
700 1 _ |a Feng, Ruoqing
|0 P:(DE-2719)9002625
|b 1
|u dzne
700 1 _ |a Yuan, Xidi
|0 P:(DE-2719)9002065
|b 2
|u dzne
700 1 _ |a Liu, Lu
|0 P:(DE-2719)9002890
|b 3
700 1 _ |a Klein, Dennis
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Hutahaean, Gladis
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Butz, Elisabeth
|0 P:(DE-2719)9003033
|b 6
|u dzne
700 1 _ |a Wang, Zhen
|0 P:(DE-2719)9003032
|b 7
|u dzne
700 1 _ |a Steinbrecher, Lisa
|0 P:(DE-2719)9000776
|b 8
|u dzne
700 1 _ |a Neher, Jonas
|0 P:(DE-2719)2811021
|b 9
700 1 _ |a Martini, Rudolf
|b 10
700 1 _ |a Simons, Mikael
|0 P:(DE-2719)2811642
|b 11
|e Last author
773 _ _ |a 10.1038/s41593-025-01955-w
|g Vol. 28, no. 6, p. 1160 - 1173
|0 PERI:(DE-600)1494955-6
|n 6
|p 1160 - 1173
|t Nature neuroscience
|v 28
|y 2025
|x 1097-6256
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/279051/files/DZNE-2025-00681.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/279051/files/DZNE-2025-00681.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:279051
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002589
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002625
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002065
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002890
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9003033
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9003032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9000776
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811021
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811642
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-07
915 _ _ |a DEAL Nature
|0 StatID:(DE-HGF)3003
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b NAT NEUROSCI : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 0
920 1 _ |0 I:(DE-2719)1110011
|k AG Neher (München)
|l Neuroimmunology and Neurodegenerative Disease
|x 1
920 1 _ |0 I:(DE-2719)1210012
|k AG Neher (Tübingen)
|l Neuroimmunology and Neurodegenerative Disease
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1110011
980 _ _ |a I:(DE-2719)1210012
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21